New drug a major breakthrough for CF patients in Ireland – Roche

A new drug has been approved for the treatment of cystic fibrosis (CF) and is a critical development for over 1,400 people living with CF in Ireland, a Fine Gael TD has said.

Deputy Pete Roche said that Alyftrek, a drug manufactured by Vertex Pharmaceuticals, has been approved by the European Commission for use across the EU for individuals ages six and over with at least one non-class I mutation in the CFTR gene.

Deputy Roche said: “This is truly fantastic news for those living with cystic fibrosis in Ireland and their families. This new therapy has shown strong clinical results and its approval means a new generation of highly effective and sustainable treatments will now become available.

“Access to this therapy is not just a medical issue — it’s a matter of dignity, equity, and public health.

“Ireland has one of the highest rates of CF in the world, and it’s critical that we stay at the forefront of treatment access.

“This approval also reflects the importance of sustained investment in medical innovation. It’s a reminder that we must continue to support research and swift access to treatment, especially for rare and chronic conditions.

“The next step is to ensure Alyftrek is made available to patients across Ireland as soon as possible. I will continue to advocate on behalf of patients and to engage with the HSE, Vertex and all stakeholders to ensure all eligible patients can access this medication without any delay.”